SUNNYVALE, Calif., Feb. 20 /PRNewswire/ -- Biocircuits Corporation
(Nasdaq: BIOC) announced a 1-for-2.5 reverse stock split of its Common Stock,
effective as of February 23, 1998.  The reverse split, approved by
shareholders at the June 1997 annual meeting, will reduce the number of Common
shares outstanding to 7.0 million from 17.5 million.
    "The amendments to the Nasdaq National Market Listing Requirements,
approved by the SEC on August 22, 1997, required listed companies to maintain
a minimum bid price of $1.00 and eliminated any alternative tests.  This
change required the Company to initiate this action in order to achieve
compliance with the Nasdaq Listing Requirements," stated John Kaiser,
President and CEO.
    The number of shares of the Company's Series A Preferred Stock outstanding
remains unchanged at 11.2 million.  Upon conversion of Preferred Stock,
shareholders will receive .10 shares of Common Stock for each share of
Preferred.  With all shares of Preferred Stock converted, Biocircuits will
have a total of 8.1 million shares of Common Stock outstanding.
    Biocircuits' IOS(R) system is the first easy to use and economical system
for performing immunoassays in the physician's office. Although approximately
36,000 sites currently have the requisite moderate complex license for
performing such tests, most send the testing out to large laboratories since
an appropriate system performing such tests has not been available.
Currently, four cartridges are available for use on the system, a T4/T Uptake
combination, TSH, T4/TSH combination and Quantitative hCG.  In addition, a PSA
cartridge, a Free T4 cartridge and a Digoxin cartridge are currently all in
various stages of clinical evaluation.

Link to this page: